IGF-1 and atherothrombosis: Relevance to pathophysiology and therapy
Clinical Science, ISSN: 0143-5221, Vol: 120, Issue: 9, Page: 377-402
2011
- 57Citations
- 65Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations57
- Citation Indexes57
- 57
- CrossRef46
- Captures65
- Readers65
- 65
Review Description
IGF-1 (insulin-like growth factor-1) plays a unique role in the cell protection of multiple systems, where its fine-tuned signal transduction helps to preserve tissues from hypoxia, ischaemia and oxidative stress, thus mediating functional homoeostatic adjustments. In contrast, its deprivation results in apoptosis and dysfunction. Many prospective epidemiological surveys have associated low IGF-1 levels with late mortality, MI (myocardial infarction), HF (heart failure) and diabetes. Interventional studies suggest that IGF-1 has anti-atherogenic actions, owing to its multifaceted impact on cardiovascular risk factors and diseases. The metabolic ability of IGF-1 in coupling vasodilation with improved function plays a key role in these actions. The endothelial-protective, anti-platelet and anti-thrombotic activities of IGF-1 exert critical effects in preventing both vascular damage and mechanisms that lead to unstable coronary plaques and syndromes. The pro-survival and anti-inflammatory short-term properties of IGF-1 appear to reduce infarct size and improve LV (left ventricular) remodelling after MI. An immune-modulatory ability, which is able to suppress 'friendly fire' and autoreactivity, is a proposed important additional mechanism explaining the anti-thrombotic and anti-remodelling activities of IGF-1. The concern of cancer risk raised by long-term therapy with IGF-1, however, deserves further study. In the present review, we discuss the large body of published evidence and review data on rhIGF-1 (recombinant human IGF-1) administration in cardiovascular disease and diabetes, with a focus on dosage and safety issues. Perhaps the time has come for the regenerative properties of IGF-1 to be assessed as a new pharmacological tool in cardiovascular medicine. © The Authors Journal compilation © 2011 Biochemical Society.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=79951782444&origin=inward; http://dx.doi.org/10.1042/cs20100400; http://www.ncbi.nlm.nih.gov/pubmed/21244364; https://portlandpress.com/clinsci/article/120/9/377/68882/IGF-1-and-atherothrombosis-relevance-to; http://clinsci.org/lookup/doi/10.1042/CS20100400; https://dx.doi.org/10.1042/cs20100400; https://portlandpress.com/clinsci/article-abstract/120/9/377/68882/IGF-1-and-atherothrombosis-relevance-to?redirectedFrom=fulltext; https://portlandpress.com/clinsci/article-pdf/120/9/377/442169/cs1200377.pdf; https://portlandpress.com/clinsci/article/120/9/377/68882/IGF1-and-atherothrombosis-relevance-to; http://www.clinsci.org/lookup/doi/10.1042/CS20100400; http://www.clinsci.org/content/120/9/377; http://www.clinsci.org/content/120/9/377.abstract; http://www.clinsci.org/content/120/9/377.full.pdf; http://europepmc.org/abstract/med/21244364; http://www.clinsci.org/cs/120/cs1200377.htm; http://www.clinsci.org/content/ppclinsci/120/9/377.full.pdf; https://portlandpress.com/clinsci/article/120/9/377-402/68882; http://www.clinsci.org/cgi/doi/10.1042/CS20100400
Portland Press Ltd.
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know